Gerresheimer stock falls after the latest board shake-up
Published on 08/27/2026 at 08:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gerresheimer AG (DE000A0LD6E6) traded at $25.58 on August 25, 2026, after a 8.71 percent drop, while its market cap was $1.04 billion and volume reached 449,875 shares. The move came as investors digested a fresh board-level change and the market kept a close eye on the company ahead of its August 27, 2026 reporting slot.
Market setup
The latest quoted session also placed Gerresheimer inside a 52-week range of $19.17 to $56.75, with the stock still well below the top of that band. On a longer view, the shares were down 7.25 percent for the year and 8.58 percent over five days, which shows how fast sentiment has cooled after a strong spring rebound.
That backdrop matters because the current valuation is still anchored to a forward P/E of 9.73 and an enterprise value to EBITDA ratio of 10.00, both taken from the August 2026 market snapshot. The same snapshot also showed total debt to equity at 144.53 percent, a level that keeps balance-sheet scrutiny high.
What analysts see
Gerresheimer's analyst consensus currently stands at 12 firms with an average target of EUR 27.05, which leaves only a 5.73 percent gap to the latest closing level shown in the market data. The rating mix is neutral rather than bullish, and that matters more now that the share price has moved sharply lower in the past week.
Historically, the business was already under pressure in Q4 FY25, when revenue came in at $639.5 million and the stock data source showed a trailing net loss of $320.32 million on revenue of $2.32 billion. Those figures help explain why investors remain sensitive to any shift in guidance, margin, or cash conversion.
Business focus
Gerresheimer's core products include prefillable syringes, vials, glass cartridges, inhalers, and injection systems, all of which sit inside its plastics and device as well as primary packaging glass divisions. That product mix makes the company a direct play on pharma packaging demand rather than a broad consumer-health story.
A recent market note also flagged the company after the interim leadership change, which kept trading attention fixed on execution at a time when the stock had already fallen 8.71 percent in one session. For investors, the most important numbers now are the August 25 price, the EUR 27.05 consensus target, and the 9.73 forward P/E.
Price and venue
Gerresheimer shares were last quoted at $25.58 on August 25, 2026 in the market snapshot, with the OTC listing shown as GRRMF and the home market quote at GXI. The latest session also showed a 52-week low of $19.17 and a 52-week high of $56.75.
Fact box
Company: Gerresheimer AG
ISIN: DE000A0LD6E6
Ticker: GXI / GRRMF
Exchange: Xetra / OTC Markets
Price (as of August 25, 2026): $25.58 USD
Market cap: $1.04 billion
Sector / Industry: Healthcare / Medical Instruments & Supplies
Index membership: SDAX
